Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients

Recently, it was reported that soluble MICB (sMICB) may impair tumor immunogenicity by reducing natural killer group 2D ligand densities on malignant cells. The aim of this study was to elucidate the role of sMICB in melanoma patients. In the present study, we determined sMICB serum concentration in...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2013-02, Vol.34 (1), p.565-569
Main Authors: Wu, Bao-Jin, Li, Wen-Peng, Qian, Cheng, Ding, Wei, Zhou, Zhong-Wen, Jiang, Hua
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - blood
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cisplatin - therapeutic use
Dacarbazine - analogs & derivatives
Dacarbazine - therapeutic use
Disease Progression
Disease-Free Survival
Female
Histocompatibility Antigens Class I - blood
Humans
Interferon-alpha - therapeutic use
Kaplan-Meier Estimate
Ligands
Male
Medical prognosis
Melanoma - blood
Melanoma - drug therapy
Melanoma - metabolism
Research Article
Skin cancer
Vincristine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, it was reported that soluble MICB (sMICB) may impair tumor immunogenicity by reducing natural killer group 2D ligand densities on malignant cells. The aim of this study was to elucidate the role of sMICB in melanoma patients. In the present study, we determined sMICB serum concentration in 125 melanoma patients of different clinical stages of disease compared with 30 healthy controls using an ELISA. The correlations between sMICB serum concentration and clinicopathologic variables were analyzed. sMICB serum level was significantly elevated ( P  
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-012-0582-1